Sanofi's corporate venturing unit was among the new investors in a round that will support the advancement of Selecta's gout treatment through Phase 1 trials.
US-based immunotherapeutic developer Selecta Biosciences closed a $38m series E round on Tuesday backed by Sanofi-Genzyme BioVentures, a corporate venturing subsidiary of pharmaceutical firm Sanofi.
Investment firm OrbiMed led the round, which also featured Ridgeback Capital Management, Osage University Partners, AJU IB Investment, Sphera Global Health Care Fund and all Selecta’s existing investors, which include Rusnano, Flagship Ventures, NanoDimension, Leukon Investments and Polaris Venture Partners.
Selecta will use the cash to advance several product candidates from its Synthetic Vaccine Particle…
